Gemcitabine, paclitaxel, and oxaliplatin (GEMPOX) in the treatment of relapsed/refractory intracranial nongerminomatous germ cell tumors.
Intracranial germ cell tumors (GCT) account for less than 5% of all central nervous system tumors in children in Western countries. Approximately 40% are nongerminomatous GCT (NGGCT). Despite correct treatment, 16% to 47% of the patients will relapse. There are no standard approaches in case of recurrence, and treatment in this situation remains a challenge. We report three patients diagnosed with relapsed intracranial NGGCT treated with gemcitabine, paclitaxel, and oxaliplatin, in whom the tumor showed a remarkable response with normalization of tumor markers.
['Perez-Somarriba|Marta|M|', 'Moreno-Tejero|Maria Luisa|ML|', 'Rozas|Maria Isabel|MI|', 'Pelaez|Irene|I|', 'Madero|Luis|L|', 'Lassaletta|Alvaro|A|0000-0003-2881-1473']
D000293:Adolescent D000971:Antineoplastic Combined Chemotherapy Protocols D001932:Brain Neoplasms D002648:Child D003841:Deoxycytidine D019008:Drug Resistance, Neoplasm D006801:Humans D008297:Male D009364:Neoplasm Recurrence, Local D009373:Neoplasms, Germ Cell and Embryonal D000077150:Oxaliplatin D017239:Paclitaxel D011379:Prognosis D016879:Salvage Therapy D013736:Testicular Neoplasms
gemcitabine paclitaxel oxaliplatin GEMPOX NGGCT relapsed intracranial nongerminomatous germ cell tumors